Education
About Us
Working with TipRanks
Follow Us
Mersana Therapeutics Inc (MRSN)
NASDAQ:MRSN
RESEARCH TOOLSreports
MRSN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.46 - $5.96
Previous CloseN/A
Volume429.52K
Average Volume (3M)4.35M
Market Cap
$62.47M
Enterprise Value$108.28M
Total Cash (Recent Filing)$107.75M
Total Debt (Recent Filing)$28.60M
Price to Earnings (P/E)―
Beta2.70
Next Earnings
May 12, 2025EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.56
Shares Outstanding124,631,340
10 Day Avg. Volume3,516,448
30 Day Avg. Volume4,347,507
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.68
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market Cap1.73
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.67
Enterprise Value/Ebitda-1.66
Forecast
1Y Price Target
$4.67Price Target Upside834.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Mersana Therapeutics News
See All MRSN News
---
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyEmi-Li continues to show the best response rate among post Topo-I ADC treated TNBC patients, which is an area with high unmet need.
Competitive AdvantagePfizer's discontinuation of their B7-H4-targeted ADC positions Emi-Le as the leading competing asset.
Bears Say
Patient Pool LimitationPatients with 5 or more prior lines of therapy will be excluded from expansion, which may limit the patient pool.
---
Ownership Overview
17.71% Insiders
8.98% Mutual Funds
51.23% Other Institutional Investors
11.24% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MRSN FAQ
What was Mersana Therapeutics Inc’s price range in the past 12 months?
Mersana Therapeutics Inc lowest stock price was $0.46 and its highest was $5.96 in the past 12 months.
What is Mersana Therapeutics Inc’s market cap?
Mersana Therapeutics Inc’s market cap is $62.47M.
When is Mersana Therapeutics Inc’s upcoming earnings report date?
Mersana Therapeutics Inc’s upcoming earnings report date is May 12, 2025 which is in 61 days.
How were Mersana Therapeutics Inc’s earnings last quarter?
Mersana Therapeutics Inc released its earnings results on Mar 03, 2025. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.16 by $0.05.
Is Mersana Therapeutics Inc overvalued?
According to Wall Street analysts Mersana Therapeutics Inc’s price is currently Undervalued.
Does Mersana Therapeutics Inc pay dividends?
Mersana Therapeutics Inc does not currently pay dividends.
What is Mersana Therapeutics Inc’s EPS estimate?
Mersana Therapeutics Inc’s EPS estimate is -0.19.
How many shares outstanding does Mersana Therapeutics Inc have?
Mersana Therapeutics Inc has 124,631,340 shares outstanding.
What happened to Mersana Therapeutics Inc’s price movement after its last earnings report?
Mersana Therapeutics Inc reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.16. Following the earnings report the stock price went down -7.692%.
Which hedge fund is a major shareholder of Mersana Therapeutics Inc?
Currently, no hedge funds are holding shares in MRSN
---
Mersana Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.67 (834.00% Upside)
$4.67 (834.00% Upside)
Hedge Fund Trend
Increased
By 9.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days >0.1%
Last 30 Days ▲ 21.2%
Last 30 Days ▲ 21.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-91.33%
12-Months-Change
Fundamentals
Return on Equity
-505.14%
Trailing 12-Months
Asset Growth
-36.01%
Trailing 12-Months
Company Description
Mersana Therapeutics Inc
Mersana Therapeutics, Inc. engages in the development and manufacture of antibody drug conjugates to improve patient outcomes in multiple oncology indications. Its lead product candidates are XMT-1522, which focuses on breast cancer and non-small cell lung cancer (NSCLC); and XMT-1536, which targets ovarian cancer and NSCLC. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.
---
MRSN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive outlook for Mersana, highlighted by promising clinical data and a strong safety profile for Emi-Le, as well as increased collaboration revenues and reduced net loss. However, dose management challenges and market competition remain areas of concern.Read More>---
MRSN Stock 12 Month Forecast
Average Price Target
$4.67
▲(834.00% Upside)
Technical Analysis
Sarepta Therapeutics
―
MacroGenics
―
Karyopharm Therapeutics
―
TG Therapeutics
―
Blueprint Medicines
―
Best Analysts Covering MRSN
1 Year
1 Year Success Rate
7/28 ratings generated profit
1 Year Average Return
-28.39%
reiterated a buy rating 10 days ago
Copying Jonathan Chang's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -28.39% per trade.
---